Aytu Biopharma (AYTU) Payables (2011 - 2026)

Aytu Biopharma (AYTU) has 16 years of Payables data on file, last reported at $13.2 million in Q1 2026.

• Payables for Q1 2026 came in at $13.2 million, up 9.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.2 million (up 9.74% YoY), and the FY2025 annual result was $10.6 million, down 16.59% from the prior year.
• Payables slipped to $13.2 million in Q1 2026 per AYTU's latest filing, from $14.3 million in the prior quarter.
• Over five years, Payables peaked at $25.1 million in Q1 2023 and troughed at $10.6 million in Q2 2025.
• A 5-year average of $14.5 million and a median of $14.3 million in 2025 frame the typical range for Payables.
• The sharpest annual moves came in 2023 and 2024: Payables jumped 125.3% in 2023, then sank 51.92% in 2024.
• A 5-year view of Payables shows it stood at $18.0 million in 2022, then slumped by 36.15% to $11.5 million in 2023, then jumped by 36.63% to $15.7 million in 2024, then fell by 9.24% to $14.3 million in 2025, then declined by 7.33% to $13.2 million in 2026.
• Business Quant data shows AYTU's Payables at $13.2 million in Q1 2026, $14.3 million in Q4 2025, and $12.3 million in Q3 2025.